Table 2

Reason for discontinuation of the bDMARD in use

Reason for discontinuationTNFi, n=141SEC, n=62P value
Ineffectiveness, n (%)85 (60.3)36 (58.1)0.88
Adverse events, n (%)26 (18.4)17 (27.4)0.19
 Infection, n24*
 Malignancy, n1†0
 Allergic reaction, n43
 Paradoxical psoriasis, n12‡
 Uveitis, n00
 Inflammatory bowel disease, n02
 Other adverse events, n40
 Information lacking, n146
Remission, n (%)4 (2.8)2 (3.2)1.00
Other, n (%)26 (18.5)7 (11.3)0.22
  • *One severe infection requiring hospitalisation.

  • †Reoccurrence of breast cancer.

  • ‡Induced by previous TNFi and reactivated after switching to SEC; other adverse events include: headache, generalised peripheral pain, acne conglobata, diffuse adverse events.

  • bDMARD, biological disease-modifying antirheumatic drug; SEC, secukinumab; TNFi, tumour necrosis factor inhibitor.